{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:57:57Z","timestamp":1793908677519,"version":"4.8.0"},"reference-count":204,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed non-alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver disease worldwide. Its disease spectrum begins with simple steatosis, progresses through steatohepatitis (MASH, formerly NASH) and liver fibrosis, and can eventually advance to cirrhosis and even hepatocellular carcinoma. With deeper insight into its metabolic nature, the nomenclature of this disease has been updated from NAFLD to MASLD. During the transition from simple lipid accumulation to necroinflammation, excessive activation of innate immunity constitutes a decisive step, and the NLRP3 inflammasome serves as a central hub linking hepatic metabolic stress to sterile inflammation. The NLRP3 inflammasome is assembled from the sensor protein NLRP3, the adaptor protein ASC, and the effector protein pro-caspase-1, and is triggered by a two-signal model comprising priming and activation. In the metabolic microenvironment of MASLD, multiple danger signals\u2014including free fatty acids, cholesterol crystals, reactive oxygen species, molecules released from damaged mitochondria, endoplasmic reticulum stress, and gut-derived lipopolysaccharide\u2014can drive its activation in hepatocytes, Kupffer cells, hepatic stellate cells, and other cell types. Subsequently, caspase-1 catalyzes the maturation of IL-1\u03b2 and IL-18 and cleaves gasdermin D to mediate hepatocyte pyroptosis, thereby amplifying liver inflammation, promoting stellate cell activation and extracellular matrix deposition, and contributing to inflammation-associated hepatocellular carcinoma. Given its pivotal position in this pathological network, targeting the NLRP3 inflammasome is considered a promising strategy to simultaneously curb inflammation and fibrosis. This narrative review examines the structure and activation mechanisms of the NLRP3 inflammasome and its roles in each stage of MASLD progression, summarizes current research on multi-level intervention strategies\u2014represented by synthetic inhibitors, natural products, traditional Chinese medicine, and metabolic regulation\u2014and analyzes current deficiencies in clinical translation, thereby providing a reference for future mechanistic studies and drug development.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1924392","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:46:06Z","timestamp":1785822366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The NLRP3 inflammasome in metabolic dysfunction-associated steatotic liver disease: role and advances in therapeutic targeting"],"prefix":"10.3389","volume":"17","author":[{"given":"Sheng","family":"Wei","sequence":"first","affiliation":[{"name":"Department of General Medicine, The Second Affiliated Hospital of Wannan Medical College","place":["Wuhu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Shaoyang Central Hospital","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Shaoyang Central Hospital","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Shaoyang Central Hospital","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322564","article-title":"Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach","volume":"71","author":"Younes","year":"2022","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cmet.2017.06.018","article-title":"Inflammasomes on the crossroads of innate immune recognition and metabolic control","volume":"26","author":"Pr\u00f3chnicki","year":"2017","journal-title":"Cell Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.05.004","article-title":"NLRP3 inflammasomes link inflammation and metabolic disease","volume":"32","author":"De Nardo","year":"2011","journal-title":"Trends Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.03.035","article-title":"Inflammasomes in liver diseases","volume":"57","author":"Szabo","year":"2012","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(04)00046-9","article-title":"NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder","volume":"20","author":"Agostini","year":"2004","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature10759","article-title":"Inflammasomes in health and disease","volume":"481","author":"Strowig","year":"2012","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101405","article-title":"The inflammasome NLRs in immunity, inflammation, and associated diseases","volume":"29","author":"Davis","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132715","article-title":"The inflammasomes: guardians of the body","volume":"27","author":"Martinon","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.02.008","article-title":"Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes","volume":"156","author":"Lu","year":"2014","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41586-022-05570-8","article-title":"Cryo-EM structures of the active NLRP3 inflammasome disc","volume":"613","author":"Xiao","year":"2023","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-\u03baB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Mu\u00f1oz-Planillo","year":"2013","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.1184003","article-title":"The NLRP3 inflammasome: a sensor for metabolic danger","volume":"327","author":"Schroder","year":"2010","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nm1415","article-title":"Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance","volume":"12","author":"Netea","year":"2006","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature15514","article-title":"Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death","volume":"526","author":"Shi","year":"2015","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nature15541","article-title":"Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling","volume":"526","author":"Kayagaki","year":"2015","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jhep.2020.04.001","article-title":"Lytic cell death in metabolic liver disease","volume":"73","author":"Gautheron","year":"2020","journal-title":"J Hepatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41419-019-1678-y","article-title":"Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis","volume":"10","author":"Tsurusaki","year":"2019","journal-title":"Cell Death Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.139","article-title":"Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion","volume":"25","author":"He","year":"2015","journal-title":"Cell Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature18590","article-title":"Pore-forming activity and structural autoinhibition of the gasdermin family","volume":"535","author":"Ding","year":"2016","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201694696","article-title":"GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death","volume":"35","author":"Sborgi","year":"2016","journal-title":"EMBO J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1607769113","article-title":"GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes","volume":"113","author":"Aglietti","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11","volume":"479","author":"Kayagaki","year":"2011","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03218-7","article-title":"NINJ1 mediates plasma membrane rupture during lytic cell death","volume":"591","author":"Kayagaki","year":"2021","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2071-9","article-title":"Gasdermin E suppresses tumour growth by activating anti-tumour immunity","volume":"579","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2237","article-title":"Regulation of inflammasome signaling","volume":"13","author":"Rathinam","year":"2012","journal-title":"Nat Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201602089","article-title":"The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation","volume":"213","author":"Sharma","year":"2016","journal-title":"J Cell Biol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molcel.2017.08.017","article-title":"NLRP3 phosphorylation is an essential priming event for inflammasome activation","volume":"68","author":"Song","year":"2017","journal-title":"Mol Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2749","article-title":"Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity","volume":"14","author":"Hara","year":"2013","journal-title":"Nat Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.11.009","article-title":"Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity","volume":"49","author":"Py","year":"2013","journal-title":"Mol Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13727","article-title":"The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3","volume":"7","author":"Song","year":"2016","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1980","article-title":"Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome","volume":"12","author":"Nakahira","year":"2011","journal-title":"Nat Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.08.001","article-title":"Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation","volume":"39","author":"Iyer","year":"2013","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1831","article-title":"Thioredoxin-interacting protein links oxidative stress to inflammasome activation","volume":"11","author":"Zhou","year":"2010","journal-title":"Nat Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nat Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24341","article-title":"Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells","volume":"54","author":"Csak","year":"2011","journal-title":"Hepatology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1194\/jlr.M037861","article-title":"Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes\/macrophages","volume":"54","author":"L'homme","year":"2013","journal-title":"J Lipid Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PloS One"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3VMA1215-579RR","article-title":"Oxidized phosphatidylcholine induces the activation of NLRP3 inflammasome in macrophages","volume":"101","author":"Yeon","year":"2017","journal-title":"J Leukoc Biol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cell.2017.12.013","article-title":"Western diet triggers NLRP3-dependent innate immune reprogramming","volume":"172","author":"Christ","year":"2018","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.01.009","article-title":"Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis","volume":"36","author":"Shimada","year":"2012","journal-title":"Immunity"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301490","article-title":"Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation","volume":"191","author":"Heid","year":"2013","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-018-0177-6","article-title":"Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis","volume":"99","author":"Zhang","year":"2019","journal-title":"Lab Invest"},{"key":"B80","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2015.12.057","article-title":"NF-\u03baB restricts inflammasome activation via elimination of damaged mitochondria","volume":"164","author":"Zhong","year":"2016","journal-title":"Cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1053\/j.gastro.2018.09.010","article-title":"Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage-mediated hepatic inflammation and fibrosis in mice","volume":"155","author":"Luo","year":"2018","journal-title":"Gastroenterology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J Hepatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12302","article-title":"Enhancement of endothelial permeability by free fatty acid through lysosomal cathepsin B-mediated Nlrp3 inflammasome activation","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nature11290","article-title":"Novel role of PKR in inflammasome activation and HMGB1 release","volume":"488","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nature04515","article-title":"Cryopyrin activates the inflammasome in response to toxins and ATP","volume":"440","author":"Mariathasan","year":"2006","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.04.022","article-title":"NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis","volume":"145","author":"Elinav","year":"2011","journal-title":"Cell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2010.03.052","article-title":"Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice","volume":"139","author":"Miura","year":"2010","journal-title":"Gastroenterology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.1038\/ncomms7734","article-title":"Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome","volume":"6","author":"Macia","year":"2015","journal-title":"Nat Commun"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10610-0","article-title":"Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation","volume":"18","author":"Feng","year":"2024","journal-title":"Hepatol Int"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102618","article-title":"Bile acids activate NLRP3 inflammasome, promoting murine liver inflammation or fibrosis in a cell type-specific manner","volume":"10","author":"Holtmann","year":"2021","journal-title":"Cells"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13796","article-title":"Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis","volume":"7","author":"Gong","year":"2016","journal-title":"Oncotarget"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6489012","article-title":"Role of NLRP3 inflammasome in the progression of NAFLD to NASH","volume":"2016","author":"Wan","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree","year":"2014","journal-title":"Hepatology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J Mol Med (Berl)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100255108","article-title":"Inflammasome is a central player in the induction of obesity and insulin resistance","volume":"108","author":"Stienstra","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B107","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cmet.2010.11.011","article-title":"The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity","volume":"12","author":"Stienstra","year":"2010","journal-title":"Cell Metab"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J Hepatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis","volume":"75","author":"Xiong","year":"2019","journal-title":"Mol Cell"},{"key":"B111","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"B112","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108626","article-title":"Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH","volume":"34","author":"Daemen","year":"2021","journal-title":"Cell Rep"},{"key":"B115","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis","volume":"53","author":"Tran","year":"2020","journal-title":"Immunity"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"B117","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"Guilliams","year":"2022","journal-title":"Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J Hepatol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/biology9110395","article-title":"Emerging roles of liver sinusoidal endothelial cells in nonalcoholic steatohepatitis","volume":"9","author":"Furuta","year":"2020","journal-title":"Biol (Basel)"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"B121","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jhep.2023.04.037","article-title":"Intestinal B cells license metabolic T-cell activation in NASH microbiota\/antigen-independently and contribute to fibrosis by IgA-FcR signalling","volume":"79","author":"Kotsiliti","year":"2023","journal-title":"J Hepatol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.immuni.2024.01.009","article-title":"Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis","volume":"57","author":"Savage","year":"2024","journal-title":"Immunity"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.12.037","article-title":"Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes","volume":"150","author":"Hirsova","year":"2016","journal-title":"Gastroenterology"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"Ibrahim","year":"2018","journal-title":"Gut"},{"key":"B125","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm.4453","article-title":"The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.040","article-title":"Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice","volume":"68","author":"Xu","year":"2018","journal-title":"J Hepatol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J Hepatol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1038\/s41467-020-16092-0","article-title":"Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis","volume":"11","author":"An","year":"2020","journal-title":"Nat Commun"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.041","article-title":"Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis","volume":"74","author":"Gaul","year":"2021","journal-title":"J Hepatol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1055\/s-0040-1708540","article-title":"The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis","volume":"40","author":"Knorr","year":"2020","journal-title":"Semin Liver Dis"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metab"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29914","article-title":"Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis","volume":"68","author":"van der Windt","year":"2018","journal-title":"Hepatology"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.07.001","article-title":"ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development","volume":"26","author":"Nakagawa","year":"2014","journal-title":"Cancer Cell"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2015.63","article-title":"Estrogen suppresses hepatocellular carcinoma cells through ER\u03b2-mediated upregulation of the NLRP3 inflammasome","volume":"95","author":"Wei","year":"2015","journal-title":"Lab Invest"},{"key":"B148","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.04.003","article-title":"NLRP3 and pyroptosis blockers for treating inflammatory diseases","volume":"43","author":"Coll","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J Exp Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat Commun"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.11.009","article-title":"NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice","volume":"534","author":"Wang","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.715765","article-title":"The specific NLRP3 antagonist IFM-514 decreases fibrosis and inflammation in experimental murine non-alcoholic steatohepatitis","volume":"8","author":"Torres","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01398","article-title":"Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders","volume":"66","author":"Harrison","year":"2023","journal-title":"J Med Chem"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24305","article-title":"The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model","volume":"33","author":"Thornton","year":"2025","journal-title":"Obes (Silver Spring)"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112581","article-title":"Diosgenin attenuates metabolic-associated fatty liver disease through the hepatic NLRP3 inflammasome-dependent signaling pathway","volume":"138","author":"Yu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175468","article-title":"20(S)-Protopanaxatriol ameliorates MAFLD by inhibiting NLRP3 inflammasome","volume":"940","author":"Lu","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111565","article-title":"Panaxydol extracted from Panax ginseng inhibits NLRP3 inflammasome activation to ameliorate NASH-induced liver injury","volume":"128","author":"Kim","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X25500582","article-title":"Paeoniflorin alleviates metabolic dysfunction-associated fatty liver disease by targeting STING-mediated pyroptosis via inhibiting the NLRP3 inflammasome","volume":"53","author":"Guo","year":"2025","journal-title":"Am J Chin Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121842","article-title":"STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis","volume":"129","author":"Yu","year":"2019","journal-title":"J Clin Invest"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.116007","article-title":"Hyperoside attenuates NASH-associated liver fibrosis by modulating Flot2\/TLR4 signaling and pyroptosis","volume":"169","author":"Huang","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.freeradbiomed.2016.11.037","article-title":"Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation","volume":"102","author":"Porras","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175325","article-title":"Molecular mechanism and therapeutic significance of dihydromyricetin in nonalcoholic fatty liver disease","volume":"935","author":"Gong","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"7996","DOI":"10.1038\/s41598-023-34654-2","article-title":"Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice","volume":"13","author":"Lu","year":"2023","journal-title":"Sci Rep"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29020419","article-title":"6-Shogaol ameliorates liver inflammation and fibrosis in mice on a methionine- and choline-deficient diet by inhibiting oxidative stress, cell death, and endoplasmic reticulum stress","volume":"29","author":"Yang","year":"2024","journal-title":"Molecules"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/srep24399","article-title":"A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet","volume":"6","author":"Yang","year":"2016","journal-title":"Sci Rep"},{"key":"B172","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12967-022-03495-4","article-title":"Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome","volume":"20","author":"Wu","year":"2022","journal-title":"J Transl Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00185","article-title":"Berberine inhibits Nod-like receptor family pyrin domain containing 3 inflammasome activation and pyroptosis in nonalcoholic steatohepatitis via the ROS\/TXNIP axis","volume":"11","author":"Mai","year":"2020","journal-title":"Front Pharmacol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119778","article-title":"Demethyleneberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice","volume":"281","author":"Zhang","year":"2021","journal-title":"Life Sci"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2017.1356977","article-title":"Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition","volume":"13","author":"Kim","year":"2017","journal-title":"Autophagy"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172715","article-title":"Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy","volume":"864","author":"Yu","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"B178","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"B185","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J Clin Invest"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0669-6","article-title":"FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation","volume":"21","author":"Hu","year":"2020","journal-title":"Nat Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"B196","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/nature07725","article-title":"AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC","volume":"458","author":"Hornung","year":"2009","journal-title":"Nature"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/nature07710","article-title":"AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA","volume":"458","author":"Fernandes-Alnemri","year":"2009","journal-title":"Nature"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13123","article-title":"Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia\/reperfusion","volume":"282","author":"Kim","year":"2015","journal-title":"FEBS J"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1002\/jat.4258","article-title":"PFOS facilitates liver inflammation and steatosis: an involvement of NLRP3 inflammasome-mediated hepatocyte pyroptosis","volume":"42","author":"Qin","year":"2022","journal-title":"J Appl Toxicol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107660","article-title":"Alpinetin exerts anti-inflammatory, anti-oxidative and anti-angiogenic effects through activating the Nrf2 pathway and inhibiting NLRP3 pathway in carbon tetrachloride-induced liver fibrosis","volume":"96","author":"Zhu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1924392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:46:09Z","timestamp":1785822369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1924392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":204,"alternative-id":["10.3389\/fimmu.2026.1924392"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1924392","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1924392"}}